UNITED STATES
                         SECURITIES EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                February 1, 2006
                Date of Report (Date of earliest event reported)

                             Innovate Oncology, Inc.

             (Exact name of registrant as specified in its charter)

          Nevada                   33-55254-28                 87-0438641
 (State of Incorporation)    (Commission File Number)        (IRS Employer
                                                         Identification Number)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Definitive Material Agreement.

On February 1, 2006, Innovate Oncology, Inc. ("Innovate" or "Company"),
Bioaccelerate Holdings, Inc. ("Bioaccelerate") and Avantogen Limited executed a
Share Exchange Agreement (the "Agreement"). The Agreement is filed as Exhibit
10.1 to this Current Report on Form 8-K, and is specifically incorporated herein
by reference. The Agreement includes various closing conditions,
indemnifications, termination provisions and other terms and conditions of a
nature customary in share exchange agreements. The Agreement contemplates the
consummation of transactions described below that will occur and be completed
concurrently with the closing. The Company anticipates that the transaction will
close in April 2006.
<PAGE>

Innovate and Avantogen each has a 50% stake in Resistys, Inc. ("Resistys"), a
company that develops oncology compounds. As part of the transaction, at the
closing Avantogen, either directly or through another entity, will transfer its
50% interest in Resistys to Innovate. Avantogen will transfer its stake either
directly or through a newly formed company that would be a wholly owned
subsidiary of Avantogen as of the date of formation ("Newco") or through an
affiliate of Avantogen. If formed, Newco will become a party to the Agreement.
Also at the closing, Avantogen will deliver $1 million in cash to Innovate. The
Company intends to use the funds for compound development as well as general
working capital. In addition, at the closing Avantogen will deliver to Innovate
either rights to an additional drug compound for further development and
marketing or an additional $100,000 in cash, at Avantogen's option. In exchange,
Innovate will issue and deliver to the transferor of the 50% interest in
Resistys to Innovate shares of common stock, par value $0.001 per share, of
Innovate (shares of Innovate common stock are hereinafter referred to as "Common
Stock"). The exchange will result in Avantogen owning, directly or indirectly,
approximately 54.24% of the outstanding Common Stock of Innovate on a fully
diluted basis at the close of the transaction.

Also upon closing, Innovate's Board of Directors and officers will resign.
Avantogen will designate three board members, including Dr. Richard Opara, who
is currently the Chairman of the Board of Avantogen and will serve as Chairman
of the Board of the Company immediately upon the close of the transaction.
Innovate will designate two other board members, who are currently intended to
be Dr. Frank Armstrong and Lee Cole. The Company's outgoing board is comprised
of the following officers and directors: Chairman of the Board Paul Hopper,
President Dr. Nigel Rulewski, Chief Financial Officer and Treasurer Alan Bowen,
Secretary Linden Boyne, each of whom is also a director, and Dr. Frank
Armstrong, who is a director.

The transaction has been approved unanimously by the board of each party and
will be approved by the board of Newco, to the extent formed. The consummation
of the transaction also requires approval by the shareholders of Avantogen and
Innovate. Bioaccelerate owns more than two thirds of the Company's outstanding
Common Stock. Dr. Opara owns 45% of Avantogen common stock. Bioaccelerate and
Dr. Opara have executed and delivered voting agreements and proxies regarding
the transaction, which are filed as Exhibits 10.2 and 10.3, respectively, to
this Current Report on Form 8-K. By executing and delivering the voting
agreement and proxy, Bioaccelerate ensures that Innovate's shareholders will
approve the transaction through an action by written consent. Innovate will
prepare an information statement pursuant to Regulation 14C to file with the
Securities and Exchange Commission and to distribute to its shareholders.
Avantogen intends to seek approval of the transaction by its shareholders at a
shareholder meeting, but Dr. Opara's execution and delivery of a voting
agreement and proxy makes it likely that such approval will be obtained.

In addition, prior to closing Innovate will have executed and delivered to
Avantogen a registration rights agreement reasonably satisfactory in form and
substance to Avantogen and Bioaccelerate. The transaction also is subject to the
delivery at closing of a non-competition agreement, satisfactory in form and
substance to the parties, such that the parties will not compete with the
"Business", which is defined in the Agreement as the promotion, development,
testing, design, marketing, provision or sale of any product designed or
intended to do or assist with any of the following: (i) to use antiviral agents
to treat chemoresistance; (ii) to suppress genes that counteract the effects of
conventional chemotherapeutics; or (iii) to serve as adjuvants to treat
chemoresistance.

Also the transaction is subject to completion, on or prior to the closing, of
amendments to the Company's charter documents, reasonably satisfactory in form
and in substance to the parties to reflect, among other things, (i) that the
Nevada Revised Statutes "Combinations with Interested Stockholder," "Acquisition
of Controlling Interests" and similar provisions do not apply to the transaction
or to Avantogen, Newco or their respective affiliates; and (ii) restrictions on
actions by Innovate post-closing without the prior approval of Bioaccelerate so
long as Bioaccelerate owns 20% or more of the capital stock of the Company on a
fully diluted basis, and such other matters, if any, as may be mutually agreed
by Bioaccelerate and Avantogen, unless as to item (ii), Avantogen and
Bioaccelerate agree to address such matters in a voting agreement.


                                       2
<PAGE>

The Agreement includes representations and warranties by the parties, including
among other things, specific limitations on liabilities of Innovate as of the
closing. In this connection, the parties have agreed that on or prior to the
closing, the outstanding credit line by Bioaccelerate in favor of Innovate will
have been terminated and no amounts shall be due to Bioaccelerate in respect of
the credit line. The parties anticipate that Innovate will deliver shares of
Common Stock in payment of outstanding principal and interest.

In addition to customary termination provisions and fiduciary out provisions,
each of Bioaccelerate and Avantogen may terminate the Agreement by providing
written notice to the other party within seven (7) business days of the
execution and delivery of the Agreement if one party is dissatisfied with the
schedules to the Agreement or information and documents received from the other
party.

The foregoing summary of the terms and conditions of the Agreement does not
purport to be complete and is qualified in its entirety and incorporated by
reference to the full text of the Agreement filed herein as Exhibit 10.1.

Section 8 - Other Events

Item 8.01 Other Events.

The Company issued a press release on February 2, 2006 announcing the Agreement.
That press release is filed as Exhibit 99.1 to this Current Report on Form 8-K
and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits.

(c) Exhibits.

The following exhibits are filed with this report

10.1  Share Exchange Agreement dated as of January 31, 2006 by and among
      Avantogen Limited, Bioaccelerate Holdings, Inc. and Innovate Oncology,
      Inc.

10.2  Voting Agreement and Proxy of Bioaccelerate Holdings, Inc.

10.3  Voting Agreement and Proxy of Dr. Richard Opara

99.1  Press release dated February 2, 2006


                                       3
<PAGE>

                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        Innovate Oncology, Inc.

                                        By:  /s/ Paul Hopper
                                        ---------------------------
                                        Paul Hopper
                                        Chief Executive Officer

                                        Date: February 7, 2006


                                       4
<PAGE>

                                  Exhibit Index

10.1  Share Exchange Agreement dated as of January 31, 2006 by and among
      Avantogen Limited, Bioaccelerate Holdings, Inc. and Innovate Oncology,
      Inc.

10.2  Voting Agreement and Proxy of Bioaccelerate Holdings, Inc.

10.3  Voting Agreement and Proxy of Dr. Richard Opara

99.1  Press release dated February 2, 2006


                                       5
{"company-data": {"conformed-name": "INNOVATE ONCOLOGY, INC.", "cik": "0000894538", "assigned-sic": "9995", "irs-number": "870438641", "state-of-incorporation": "NV", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "033-55254-28", "film-number": "06585787"}, "business-address": {"street1": "712 FIFTH AVENUE", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019", "phone": "646 723 8944"}, "mail-address": {"street1": "712 FIFTH AVENUE", "street2": "19TH FLOOR", "city": "NEW YORK", "state": "NY", "zip": "10019"}, "former-company": [{"former-conformed-name": "HAMPTON BERKSHIRE INSURANCE & FINANCIAL INC", "date-changed": "20030318"}, {"former-conformed-name": "FIRST CAPITAL RESOURCES COM INC", "date-changed": "19990512"}, {"former-conformed-name": "JACKAL INDUSTRIES INC", "date-changed": "19940706"}]}
UNITED STATES
                         SECURITIES EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                                February 1, 2006
                Date of Report (Date of earliest event reported)

                             Innovate Oncology, Inc.

             (Exact name of registrant as specified in its charter)

          Nevada                   33-55254-28                 87-0438641
 (State of Incorporation)    (Commission File Number)        (IRS Employer
                                                         Identification Number)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

Section 1 - Registrant's Business and Operations

Item 1.01 Entry into a Definitive Material Agreement.

On February 1, 2006, Innovate Oncology, Inc. ("Innovate" or "Company"),
Bioaccelerate Holdings, Inc. ("Bioaccelerate") and Avantogen Limited executed a
Share Exchange Agreement (the "Agreement"). The Agreement is filed as Exhibit
10.1 to this Current Report on Form 8-K, and is specifically incorporated herein
by reference. The Agreement includes various closing conditions,
indemnifications, termination provisions and other terms and conditions of a
nature customary in share exchange agreements. The Agreement contemplates the
consummation of transactions described below that will occur and be completed
concurrently with the closing. The Company anticipates that the transaction will
close in April 2006.
Innovate and Avantogen each has a 50% stake in Resistys, Inc. ("Resistys"), a
company that develops oncology compounds. As part of the transaction, at the
closing Avantogen, either directly or through another entity, will transfer its
50% interest in Resistys to Innovate. Avantogen will transfer its stake either
directly or through a newly formed company that would be a wholly owned
subsidiary of Avantogen as of the date of formation ("Newco") or through an
affiliate of Avantogen. If formed, Newco will become a party to the Agreement.
Also at the closing, Avantogen will deliver $1 million in cash to Innovate. The
Company intends to use the funds for compound development as well as general
working capital. In addition, at the closing Avantogen will deliver to Innovate
either rights to an additional drug compound for further development and
marketing or an additional $100,000 in cash, at Avantogen's option. In exchange,
Innovate will issue and deliver to the transferor of the 50% interest in
Resistys to Innovate shares of common stock, par value $0.001 per share, of
Innovate (shares of Innovate common stock are hereinafter referred to as "Common
Stock"). The exchange will result in Avantogen owning, directly or indirectly,
approximately 54.24% of the outstanding Common Stock of Innovate on a fully
diluted basis at the close of the transaction.

Also upon closing, Innovate's Board of Directors and officers will resign.
Avantogen will designate three board members, including Dr. Richard Opara, who
is currently the Chairman of the Board of Avantogen and will serve as Chairman
of the Board of the Company immediately upon the close of the transaction.
Innovate will designate two other board members, who are currently intended to
be Dr. Frank Armstrong and Lee Cole. The Company's outgoing board is comprised
of the following officers and directors: Chairman of the Board Paul Hopper,
President Dr. Nigel Rulewski, Chief Financial Officer and Treasurer Alan Bowen,
Secretary Linden Boyne, each of whom is also a director, and Dr. Frank
Armstrong, who is a director.

The transaction has been approved unanimously by the board of each party and
will be approved by the board of Newco, to the extent formed. The consummation
of the transaction also requires approval by the shareholders of Avantogen and
Innovate. Bioaccelerate owns more than two thirds of the Company's outstanding
Common Stock. Dr. Opara owns 45% of Avantogen common stock. Bioaccelerate and
Dr. Opara have executed and delivered voting agreements and proxies regarding
the transaction, which are filed as Exhibits 10.2 and 10.3, respectively, to
this Current Report on Form 8-K. By executing and delivering the voting
agreement and proxy, Bioaccelerate ensures that Innovate's shareholders will
approve the transaction through an action by written consent. Innovate will
prepare an information statement pursuant to Regulation 14C to file with the
Securities and Exchange Commission and to distribute to its shareholders.
Avantogen intends to seek approval of the transaction by its shareholders at a
shareholder meeting, but Dr. Opara's execution and delivery of a voting
agreement and proxy makes it likely that such approval will be obtained.

In addition, prior to closing Innovate will have executed and delivered to
Avantogen a registration rights agreement reasonably satisfactory in form and
substance to Avantogen and Bioaccelerate. The transaction also is subject to the
delivery at closing of a non-competition agreement, satisfactory in form and
substance to the parties, such that the parties will not compete with the
"Business", which is defined in the Agreement as the promotion, development,
testing, design, marketing, provision or sale of any product designed or
intended to do or assist with any of the following: (i) to use antiviral agents
to treat chemoresistance; (ii) to suppress genes that counteract the effects of
conventional chemotherapeutics; or (iii) to serve as adjuvants to treat
chemoresistance.

Also the transaction is subject to completion, on or prior to the closing, of
amendments to the Company's charter documents, reasonably satisfactory in form
and in substance to the parties to reflect, among other things, (i) that the
Nevada Revised Statutes "Combinations with Interested Stockholder," "Acquisition
of Controlling Interests" and similar provisions do not apply to the transaction
or to Avantogen, Newco or their respective affiliates; and (ii) restrictions on
actions by Innovate post-closing without the prior approval of Bioaccelerate so
long as Bioaccelerate owns 20% or more of the capital stock of the Company on a
fully diluted basis, and such other matters, if any, as may be mutually agreed
by Bioaccelerate and Avantogen, unless as to item (ii), Avantogen and
Bioaccelerate agree to address such matters in a voting agreement.

                                       2
The Agreement includes representations and warranties by the parties, including
among other things, specific limitations on liabilities of Innovate as of the
closing. In this connection, the parties have agreed that on or prior to the
closing, the outstanding credit line by Bioaccelerate in favor of Innovate will
have been terminated and no amounts shall be due to Bioaccelerate in respect of
the credit line. The parties anticipate that Innovate will deliver shares of
Common Stock in payment of outstanding principal and interest.

In addition to customary termination provisions and fiduciary out provisions,
each of Bioaccelerate and Avantogen may terminate the Agreement by providing
written notice to the other party within seven (7) business days of the
execution and delivery of the Agreement if one party is dissatisfied with the
schedules to the Agreement or information and documents received from the other
party.

The foregoing summary of the terms and conditions of the Agreement does not
purport to be complete and is qualified in its entirety and incorporated by
reference to the full text of the Agreement filed herein as Exhibit 10.1.

Section 8 - Other Events

Item 8.01 Other Events.

The Company issued a press release on February 2, 2006 announcing the Agreement.
That press release is filed as Exhibit 99.1 to this Current Report on Form 8-K
and incorporated herein by reference.

Section 9 - Financial Statements and Exhibits.

(c) Exhibits.

The following exhibits are filed with this report

10.1  Share Exchange Agreement dated as of January 31, 2006 by and among
      Avantogen Limited, Bioaccelerate Holdings, Inc. and Innovate Oncology,
      Inc.

10.2  Voting Agreement and Proxy of Bioaccelerate Holdings, Inc.

10.3  Voting Agreement and Proxy of Dr. Richard Opara

99.1  Press release dated February 2, 2006

                                       3
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        Innovate Oncology, Inc.

                                        By:  /s/ Paul Hopper
                                        ---------------------------
                                        Paul Hopper
                                        Chief Executive Officer

                                        Date: February 7, 2006

                                       4
Exhibit Index

10.1  Share Exchange Agreement dated as of January 31, 2006 by and among
      Avantogen Limited, Bioaccelerate Holdings, Inc. and Innovate Oncology,
      Inc.

10.2  Voting Agreement and Proxy of Bioaccelerate Holdings, Inc.

10.3  Voting Agreement and Proxy of Dr. Richard Opara

99.1  Press release dated February 2, 2006

                                       5